Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…
American Airlines Names Ex-Boeing Finance Chief As Chairman
American Airlines Group Inc (NASDAQ:AAL) has named Greg Smith as independent chairman of the company’s board of directors, effective April 30,…
GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows
ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…
GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)
Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV
EXCLUSIVE: Benzinga’s Favorite Hedge Funds To Watch During 13F Season
It’s hedge fund season.
Hedge funds with more than $100 million in assets are required to file a Form 13F with the U.S. Securities and Exchange Commission (SEC) within 45 days of the end of each calendar quarter. The last deadline was Feb. 14 for the fiscal quarter ending Dec. 31.
What’s More Expensive: Buying A House, Or Building One?
The housing market has been top-of-mind for new and would-be homeowners for months, as the Federal Reserve’s aggressive rate hike campaign has kept mortgage rates at highs last seen since 2007.
And it’s not just expensive borrowing costs keeping people in their apartments.
Astrazeneca’s Tablet Formulation Of Calquence (Acalabrutinib) Has Been Approved In The European Union (Eu) For Adult Patients With Chronic Lymphocytic Leukemia.
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the ELEVATE-PLUS trials published in the American Society of
US Supreme Court Refuses To Reject $302M Judgment Against Johnson & Johnson Over Pelvic Mesh Marketing
The U.S. Supreme Court refused to hear Johnson & Johnson's (NYSE: JNJ) regarding a $302 million judgment in a lawsuit brought by California, accusing the company of concealing the risks of its pelvic mesh products.